GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal …
Oct 14, 2024 · On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic...
Dupixent receives FDA approval as first CRSwNP treatment
Sep 16, 2024 · The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
TEZSPIRE met both co-primary endpoints in the Phase III …
Nov 8, 2024 · Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s TEZSPIRE ® (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion ...
What is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)?
People with chronic rhinosinusitis without nasal polyps may experience the same symptoms. But CRSwNP is associated with more severe symptoms. Symptoms can be triggered by anything that irritates the nasal passages. The irritation causes the nasal polyps to swell, leading to nasal congestion. Common triggers include: How common is CRSwNP?
Dupilumab for Chronic Rhinosinusitis With Nasal Polyps Is Effective
Dec 2, 2024 · Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks, researchers reported in the Journal of Allergy and Clinical Immunology. Researchers conducted an observational, retrospective study evaluating the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 tertiary
Dupilumab Demonstrates Efficacy for Severe Uncontrolled CRSwNP …
4 days ago · The US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent), an anti-T2-inflammatory biological drug, as a therapy for adults with inadequately controlled CRSwNP on June 26, 2019. 2,3 5 years later on September 13, 2024, the FDA approved dupilumab as an add-on maintenance ...
GSK's depemokimab shows promise in Phase III CRSwNP trials
Oct 15, 2024 · UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces
Oct 14, 2024 · GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be...
GSK’s Nucala Gains Approval in China for CRSwNP - Yahoo Finance
Jan 4, 2025 · GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30...
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
Jan 6, 2025 · The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in the adult population.